Samtíma inngjöf ACAT og MMP tálma til meðhöndlunar á skemmdum vegna fituhrörnunar

摘要

This invention is the coadministration of ACAT and MMP inhibitors for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development of new lesions and for the prevention of plaque rupture and the promotion of lesion regression in a mammal.